To Detect the Sensitivity of the UroMark Assay (DETECT II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02781428

Recruitment Status : Active, not recruiting

First Posted : May 24, 2016

Last Update Posted : October 9, 2019

Sponsor:

Information provided by (Responsible Party):

University College, London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	September 2020
Estimated Study Completion Date :	September 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tan WS, Teo CH, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew-Graves C, Ng CJ, Kelly JD; DETECT II trial collaborators. Mixed-methods approach to exploring patients' perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU Int. 2019 Sep;124(3):408-417. doi: 10.1111/bju.14690. Epub 2019 Mar 4.

To Top